Czech/SlovakiaCzech RepublicSlovakia

New Brno-based life sciences centre opens up for business

05.12.2011

Brno – Czech Prime Minister Petr Necas has officially inaugurated the first of six European Technology Institutes slated to be launched in the Czech Republic with help from European FEDER funds. Although construction of the €200m Central European Institute of Technology (CEITEC) will not be complete until 2014, the life sciences research centre – made up of ten facilities – has already begun operations. Following a workshop with EMBL researchers, CEITEC deputy director Ondrej Hradil announced in mid-November that the center has already been approached with several proposals for cooperation in the fields of bioinformatics, innovative sequencing techniques and development of new methods of advanced optical microscopy. Up to now, the Czech Republic has not been an EMBL member country, but CEITEC would support negotiations on its membership. Earlier in November, CEITEC ordered four ultra-high field AVANCETM NMR systems from Bruker, which will make it the premier biological NMR research facility in Central and Eastern Europe. “High-field NMR spectroscopy will be combined with other progressive high-resolution methods of structural analysis here such as single-crystal X-ray diffraction, high-end cryo-electron microscopy and tomography, and an atomic force microscopy for understanding of the vital cellular processes,” said Vladimir Sklenar, the Structural Biology Programme Coordinator at CEITEC.

Boost for biotech clusters

Bringing Brno-based research institutes into the CEITEC cluster is part of a more general governmental initiative aimed at creating big research hubs that attract foreign investment and companies. According to the Prague Post, CEITEC is already in discussions with 100 companies that want to pursue research at the site.
The other sites scheduled for opening are also designed to boost bio­technology in the Czech Republic. Along with CEITEC, Prague is aiming to launch an International Clinical Research Centre (ICRC), a Biotechnology and Biomedicine Research Centre (BIOCEV), a Sustainable Energy Centre (SUSEN), an Information Technology for Innovations (IT4I) hub, and an Extreme Light Infrastructure (ELI) cluster. 70% of the costs will be covered by state or EU funding, the rest is to be funded by private investors.

Czech/SlovakiaCzech RepublicSlovakia

11.11.2008

Prague/Tokyo – Tokyo-based Otsuka Pharmaceutical has established its first research, development and manufacturing facility in Eastern Europe. By the end of August, the diversified company had completed the acquisition of Czech...

Czech/SlovakiaCzech RepublicSlovakia

22.08.2008

Prague – Czech scientists have appealed to the European Council not to to politicise the approval process for biotech crops. “Although the EU has the strictest rules on GM plants in the world, politicians in Brussels prefer to...

Czech/SlovakiaCzech RepublicSlovakia

16.07.2008

Brno – Czech biotechnologists and EU industry experts have worked out an action plan to improve the development of industrial biotechnology in the Czech Republic. The recommendations are based on three SWOT analyses (R&D,...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Bratisava – German Lanxess, specialist for the development, manufacture and distribution of specialty chemicals and intermediates, has opened a new sales company for Central/Eastern Europe in Bratislava. This is its 3rd...

Czech/SlovakiaCzech RepublicSlovakia

20.05.2008

Prague – Gate2biotech has released a report on what’s going on in biotechnology in the Czech Republic. Windows-users can download a free electronic copy of the company registry and academic landscape or order a hardcopy at:...

Czech/SlovakiaCzech RepublicSlovakia

19.03.2008

Prague – The worldwide clinical research organisation Icon plc (Dublin, Ireland) has further expanded its activities in Eastern Europe. The CRO opened offices in Prague (Czech Republic), Kiev (Ukraine), and Bucharest (Romania),...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – The Czech Republic has increased its R&D expenditures significantly in the last year. At a1.88 billion, R&D investments rose by 18% compared to 2005, the second largest increase world-wide. Those expenditures achieved...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Kourim/Basel – Lonza Biotec s.r.o. (Kourim, Czech Republic), a specialist for microbial fermentation and manufacturing services, has completed the extension of its production plant in Kourim designed for the cGMP-compliant...

Czech/SlovakiaCzech RepublicSlovakia

22.11.2007

Prague – Prague Clinical Services s.r.o. will conduct the pivotal phase III trials in Europe for Gia­conda Ltd.’s (Sydney, Australia) lead product Myoconda®, an anti­biotic combination therapy for the treatment of MAP infection...

Czech/SlovakiaCzech RepublicSlovakia

24.09.2007

Prague/Norwood – The international clinical trial company Medpace Inc. (Norwood, USA) has acquired the Czech contract research organisation Monax s.r.o. (Prague) for an undisclosed sum. With the acquisition, which the firm...

Displaying results 21 to 30 out of 70

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-czech-slovakia/browse/2/article/new-brno-based-life-sciences-centre-opens-up-for-business.html

Events

All Events

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • THERAMETRICS (CH)0.09 CHF12.50%
  • AB SCIENCE (F)11.21 EUR9.37%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • SERODUS (N)2.81 NOK-10.79%

TOP

  • WILEX (D)2.80 EUR268.4%
  • SANTHERA (CH)65.50 CHF81.9%
  • ADDEX (CH)4.01 CHF79.0%

FLOP

  • MERCK KGAA (D)65.21 EUR-48.8%
  • HYBRIGENICS (F)1.74 EUR-28.7%
  • PROSENSA (NL)9.65 USD-23.5%

TOP

  • SANTHERA (CH)65.50 CHF3175.0%
  • GW PHARMACEUTICALS (UK)412.50 GBP630.1%
  • PAION (D)2.74 EUR315.2%

FLOP

  • CYTOS (CH)0.28 CHF-91.8%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.45 EUR-69.7%

No liability assumed, Date: 28.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products